Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Key to changes
?
Text removedfrom 2020 Q1- Text added to 2020 Q2
Content analysis
?Positive | |
Negative | |
Uncertain | |
Constraining | |
Legalese | |
Litigous | |
Readability |
H.S. junior Avg
|
Content analysis
?Positive | |
Negative | |
Uncertain | |
Constraining | |
Legalese | |
Litigous | |
Readability |
H.S. sophomore Avg
|
New words:
activitieswere, andhave, andissuance, Antitrust, AstraZeneca, aware, BioNTech, captioned, coalition, collaborationincluded, collaborationterm, Companyestimated, conductingor, consummated, contemplated, contrast, covercertain, customary, donation, endedJune, EVP, factor, fieldwould, financingsor, foradditional, Founder, French, GlaxoSmithKline, howthe, illion, inAugust, indeterminate, Johnson, knowledge, markup, Merck, Novavax, nvestor, ofJune, ofthe, partieswould, paymentswould, Pfizer, presidential, progressed, promptly, resignation, resumption, sample, Sanofidi, Sanofidid, Sanofiwould, SE, sequester, SPA, Standstill, strike, technologywa, theFirst, thenext, theOriginal, thesix, timeand, toan, toat, toextend, upcoming, vaccinestargeting, verified, Vice, waiting, weand, whichcould
Valuein 2020 Q1 filing- Value in 2020 Q2 filing
Original filings
Filing view